Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Issue 48 (27th November 2015)

• Record Type: Journal Article
• Authors: Kim, Young-In; Song, Jae-Hyoung; Kwon, Bo-Eun; Kim, Ha-Neul; Seo, Min-Duk; Park, KwiSung; Lee, SangWon; Yeo, Sang-Gu; Kweon, Mi-Na; Ko, Hyun-Jeong; Chang, Sun-Young
• Is Part Of: Vaccine. Volume 33:Issue 48(2015)
• Page Start: 6604
• Page End: 6610
• Publication Date: 2015-11-27
• Subjects: Enterovirus 71 -- VP1 -- Maternal IgG -- Protective immunity -- Pre-existing immunity; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.10.103
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Enterovirus 71 (EV71) causes hand, foot, and mouth diseases and can result in severe neurological disorders when it infects the central nervous system. Thus, there is a need for the development of effective vaccines against EV71 infection. Here we report that viral capsid protein 1 (VP1), one of the main capsid proteins of EV71, efficiently elicited VP1-specific immunoglobulin G (IgG) in the serum of mice immunized with recombinant VP1. The VP1-specific IgG produced in female mice was efficiently transferred to their offspring, conferring protection against EV71 infection immediately after birth. VP1-specific antibody can neutralize EV71 infection and protect host cells. VP1-specific maternal IgG in offspring was maintained for over 6 months. However, the pre-existence of VP1-specific maternal IgG interfered with the production of VP1-specific IgG antibody secreting cells by active immunization in offspring. Therefore, although our results showed the potential for VP1-specific maternal IgG protection against EV71 in neonatal mice, other strategies must be developed to overcome the hindrance of maternal IgG in active immunization. In this study, we developed an effective and feasible animal model to evaluate the protective efficacy of humoral immunity against EV71 infection using a maternal immunity concept.